Switch theme
Sign up to access all valuation multiples
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
2007
294
LTM Revenue $26.4M
LTM EBITDA -$23.9M
$158M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ryvu Therapeutics has a last 12-month revenue (LTM) of $26.4M and a last 12-month EBITDA of -$23.9M.
In the most recent fiscal year, Ryvu Therapeutics achieved revenue of $20.7M and an EBITDA of -$25.7M.
Ryvu Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ryvu Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $26.4M | XXX | $20.7M | XXX | XXX | XXX |
| Gross Profit | $26.4M | XXX | $15.5M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | -$23.9M | XXX | -$25.7M | XXX | XXX | XXX |
| EBITDA Margin | -91% | XXX | -124% | XXX | XXX | XXX |
| EBIT | -$31.3M | XXX | -$32.3M | XXX | XXX | XXX |
| EBIT Margin | -119% | XXX | -156% | XXX | XXX | XXX |
| Net Profit | -$29.9M | XXX | -$29.6M | XXX | XXX | XXX |
| Net Margin | -113% | XXX | -143% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ryvu Therapeutics's stock price is PLN 30 (or $8).
Ryvu Therapeutics has current market cap of PLN 695M (or $184M), and EV of PLN 595M (or $158M).
See Ryvu Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $158M | $184M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ryvu Therapeutics has market cap of $184M and EV of $158M.
Ryvu Therapeutics's trades at 7.6x EV/Revenue multiple, and -6.1x EV/EBITDA.
Equity research analysts estimate Ryvu Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ryvu Therapeutics has a P/E ratio of -6.2x.
See valuation multiples for Ryvu Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $184M | XXX | $184M | XXX | XXX | XXX |
| EV (current) | $158M | XXX | $158M | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 7.6x | XXX | XXX | XXX |
| EV/EBITDA | -6.6x | XXX | -6.1x | XXX | XXX | XXX |
| EV/EBIT | -5.0x | XXX | -4.9x | XXX | XXX | XXX |
| EV/Gross Profit | 6.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.2x | XXX | -6.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRyvu Therapeutics's last 12 month revenue growth is 2%
Ryvu Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Ryvu Therapeutics's rule of 40 is -171% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ryvu Therapeutics's rule of X is -85% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ryvu Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | -91% | XXX | -124% | XXX | XXX | XXX |
| EBITDA Growth | -28% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -171% | XXX | -122% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -85% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 231% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ryvu Therapeutics acquired XXX companies to date.
Last acquisition by Ryvu Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Ryvu Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ryvu Therapeutics founded? | Ryvu Therapeutics was founded in 2007. |
| Where is Ryvu Therapeutics headquartered? | Ryvu Therapeutics is headquartered in Poland. |
| How many employees does Ryvu Therapeutics have? | As of today, Ryvu Therapeutics has 294 employees. |
| Is Ryvu Therapeutics publicy listed? | Yes, Ryvu Therapeutics is a public company listed on WAR. |
| What is the stock symbol of Ryvu Therapeutics? | Ryvu Therapeutics trades under RVU ticker. |
| When did Ryvu Therapeutics go public? | Ryvu Therapeutics went public in 2011. |
| Who are competitors of Ryvu Therapeutics? | Similar companies to Ryvu Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ryvu Therapeutics? | Ryvu Therapeutics's current market cap is $184M |
| What is the current revenue of Ryvu Therapeutics? | Ryvu Therapeutics's last 12 months revenue is $26.4M. |
| What is the current revenue growth of Ryvu Therapeutics? | Ryvu Therapeutics revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Ryvu Therapeutics? | Current revenue multiple of Ryvu Therapeutics is 6.0x. |
| Is Ryvu Therapeutics profitable? | Yes, Ryvu Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ryvu Therapeutics? | Ryvu Therapeutics's last 12 months EBITDA is -$23.9M. |
| What is Ryvu Therapeutics's EBITDA margin? | Ryvu Therapeutics's last 12 months EBITDA margin is -91%. |
| What is the current EV/EBITDA multiple of Ryvu Therapeutics? | Current EBITDA multiple of Ryvu Therapeutics is -6.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
